Gilead Sciences (GILD) : Cambridge Advisors reduced its stake in Gilead Sciences by 3.0% during the most recent quarter end. The investment management company now holds a total of 8,739 shares of Gilead Sciences which is valued at $714,763 after selling 270 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Gilead Sciences makes up approximately 0.32% of Cambridge Advisors’s portfolio.
Other Hedge Funds, Including , Hendershot Investments reduced its stake in GILD by selling 60 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 81,460 shares of GILD which is valued at $6,662,613. Gilead Sciences makes up approx 3.30% of Hendershot Investments’s portfolio.Skylands Capital reduced its stake in GILD by selling 8,800 shares or 32.35% in the most recent quarter. The Hedge Fund company now holds 18,400 shares of GILD which is valued at $1,504,936. Gilead Sciences makes up approx 0.23% of Skylands Capital’s portfolio.Sonora Investment Management reduced its stake in GILD by selling 96 shares or 0.91% in the most recent quarter. The Hedge Fund company now holds 10,471 shares of GILD which is valued at $910,244. Gilead Sciences makes up approx 0.50% of Sonora Investment Management’s portfolio.Berson Corrado Investment Advisors reduced its stake in GILD by selling 4,683 shares or 6.48% in the most recent quarter. The Hedge Fund company now holds 67,553 shares of GILD which is valued at $5,846,712. Gilead Sciences makes up approx 2.18% of Berson Corrado Investment Advisors’s portfolio. Merriman Wealth Management added GILD to its portfolio by purchasing 14,393 company shares during the most recent quarter which is valued at $1,245,714. Gilead Sciences makes up approx 0.35% of Merriman Wealth Management’s portfolio.
Gilead Sciences closed down -1.77 points or -2.18% at $79.47 with 1,94,65,672 shares getting traded on Friday. Post opening the session at $80.6, the shares hit an intraday low of $79.37 and an intraday high of $80.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.